Just on trial design, if it is closely aligned to the P2 trial design then 13 weeks represents time-on-drug, so the overall completion time will have to be eased out a bit for each individual per graphic below. On top of that I wonder if it will be done in age group bandings, starting with the older cohort and working down. Maybe not, as that predominantly facilitates safety and tolerability concerns, and we seem to have passed those hurdles.
What I can't quite fathom is if the 13 weeks on drug is locked in, and the dose is locked in, how can you legitimately change any expectations around efficacy end points that the P2 was based on?
https://mstfinancial-au.zoom.us/rec/play/hWA8V8iIgmeCUeWMK19azFRXv5zCsKF1JtWJseW_UsbPoaNiWXmIjXFeLPcpCD3tRA-kaS03-sHa3GJU.taIYSsRUDBWrdAkJ?canPlayFromShare=true&from=share_recording_detail&startTime=1669867205000&componentName=rec-play&originRequestUrl=https%3A%2F%2Fmstfinancial-au.zoom.us%2Frec%2Fshare%2FEWkbD58v1TybkPhqDKvy8FGUJx-4C95JKyH1_BSlyS7CHiIjAXIcAHiDW9IxY9VE.ASPwHuIoxP_BIe_6%3FstartTime%3D1669867205000
Just on trial design, if it is closely aligned to the P2 trial...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.20 |
Change
0.150(1.07%) |
Mkt cap ! $1.814B | |||
| Open | High | Low | Value | Volume |
| $14.36 | $14.63 | $14.10 | $6.628M | 462.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1786 | $14.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.23 | 1786 | 1 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |